138 related articles for article (PubMed ID: 37122132)
1. Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder: An interrupted time-series analysis.
Bruno C; Zoega H; Gillies MB; Havard A; Coghill D; Pearson SA; Brett J
Aust N Z J Psychiatry; 2023 Jul; 57(7):1073-1076. PubMed ID: 37122132
[No Abstract] [Full Text] [Related]
2. Lisdexamfetamine in the treatment of attention-deficit/hyperactivity disorder in adults.
Rostain AL
Curr Psychiatry Rep; 2009 Oct; 11(5):341-2. PubMed ID: 19785973
[No Abstract] [Full Text] [Related]
3. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
Babcock T; Dirks B; Adeyi B; Scheckner B
BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273
[TBL] [Abstract][Full Text] [Related]
4. Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults.
Weber J; Siddiqui MA
CNS Drugs; 2009; 23(5):419-25. PubMed ID: 19453202
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of lisdexamfetamine dimesylate for promoting occupational success in adolescents and young adults with attention-deficit/hyperactivity disorder.
Gordon CT; Fabiano GA; Hulme KF; Sodano SM; Adragna M; Lim R; Stanford S; Janikowski L; Bufalo B; Rodriguez Z; Swiatek D
Exp Clin Psychopharmacol; 2021 Aug; 29(4):308-318. PubMed ID: 32297783
[TBL] [Abstract][Full Text] [Related]
6. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.
Adler LA; Dirks B; Deas P; Raychaudhuri A; Dauphin M; Saylor K; Weisler R
BMC Psychiatry; 2013 Oct; 13():253. PubMed ID: 24106804
[TBL] [Abstract][Full Text] [Related]
7. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
[TBL] [Abstract][Full Text] [Related]
8. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
Frampton JE
Drugs; 2018 Jul; 78(10):1025-1036. PubMed ID: 29923015
[TBL] [Abstract][Full Text] [Related]
9. Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.
Steer C; Froelich J; Soutullo CA; Johnson M; Shaw M
CNS Drugs; 2012 Aug; 26(8):691-705. PubMed ID: 22762726
[TBL] [Abstract][Full Text] [Related]
10. Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Mattingly GW; Weisler RH; Young J; Adeyi B; Dirks B; Babcock T; Lasser R; Scheckner B; Goodman DW
BMC Psychiatry; 2013 Jan; 13():39. PubMed ID: 23356790
[TBL] [Abstract][Full Text] [Related]
11. Sex subgroup analysis of treatment response to lisdexamfetamine dimesylate in children aged 6 to 12 years with attention-deficit/hyperactivity disorder.
McGough JJ; Greenbaum M; Adeyi B; Babcock T; Scheckner B; Dirks B; Findling RL
J Clin Psychopharmacol; 2012 Feb; 32(1):138-40. PubMed ID: 22217951
[No Abstract] [Full Text] [Related]
12. Randomized, double-blind, placebo-controlled, crossover study of the effects of lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout the day in adults with attention-deficit/hyperactivity disorder.
Martin PT; Corcoran M; Zhang P; Katic A
Clin Drug Investig; 2014 Feb; 34(2):147-57. PubMed ID: 24297663
[TBL] [Abstract][Full Text] [Related]
13. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial.
Coghill DR; Banaschewski T; Lecendreux M; Zuddas A; Dittmann RW; Otero IH; Civil R; Bloomfield R; Squires LA
Eur Child Adolesc Psychiatry; 2014 Feb; 23(2):61-8. PubMed ID: 23708466
[TBL] [Abstract][Full Text] [Related]
15. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
[TBL] [Abstract][Full Text] [Related]
16. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
17. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
Brams M; Giblin J; Gasior M; Gao J; Wigal T
Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420
[TBL] [Abstract][Full Text] [Related]
18. Attention-deficit/hyperactivity disorder: the road traveled and the road ahead.
Jun A
Am J Health Syst Pharm; 2009 Nov; 66(22):2003. PubMed ID: 19890082
[No Abstract] [Full Text] [Related]
19. Treating Attention-Deficit/Hyperactivity Disorder in Severe Intellectual Disability with Lisdexamfetamine: A Case Report.
Araújo A; Madeira N; Ventura F; Morais S; Coroa M; Macedo A; Areias G; Borges J
J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):490-492. PubMed ID: 34181364
[No Abstract] [Full Text] [Related]
20. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
Stuhec M; Munda B; Svab V; Locatelli I
J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
